Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

CHARM study gives heart failure hope

Major new research has backed the use of angiotensin-2-receptor antagonists (A2As) for patients with chronic heart failure.

The drug improved quality of life in more than a third of patients, according to results from the CHARM study.

The research, involving 7,600 patients, showed candesartan, an angiotensin-2-receptor blocker, improved New York Heart Association class in 35.4 per cent of patients with heart failure.

Professor John McMurray, professor of medical cardiology at the University of Glasgow, presented the findings earlier this month at the American College of Cardiology conference in New Orleans. He told Pulse the results had 'significant implications' for clinical practice.

NICE sparked controversy for failing to take account of emerging evidence on the use of A2As in heart failure when it issued guidelines last July.

It recommended GPs considered the drugs for patients who were intolerant of ACE inhibitors, which occurs in about 15 per cent of patients.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say